Marker Therapeutics (MRKR) Projected to Post Quarterly Earnings on Monday

Marker Therapeutics (NASDAQ:MRKR) is anticipated to post its quarterly earnings results before the market opens on Monday, March 24th. Analysts expect Marker Therapeutics to post earnings of ($0.28) per share and revenue of $5.25 million for the quarter.

Marker Therapeutics Price Performance

NASDAQ:MRKR opened at $1.25 on Friday. The business’s 50-day moving average price is $1.77 and its 200 day moving average price is $2.80. Marker Therapeutics has a 52-week low of $1.13 and a 52-week high of $5.99.

Wall Street Analyst Weigh In

MRKR has been the subject of several research analyst reports. Brookline Capital Management upgraded shares of Marker Therapeutics to a “strong-buy” rating in a research report on Monday, February 10th. Canaccord Genuity Group initiated coverage on shares of Marker Therapeutics in a research note on Wednesday, March 5th. They set a “buy” rating and a $8.00 target price on the stock.

Insiders Place Their Bets

In other news, Director Steve Elms bought 11,085 shares of Marker Therapeutics stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average cost of $3.20 per share, with a total value of $35,472.00. Following the completion of the transaction, the director now directly owns 325,370 shares in the company, valued at $1,041,184. This trade represents a 3.53 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Enterprise Associates 16 New acquired 554,250 shares of Marker Therapeutics stock in a transaction dated Monday, December 23rd. The shares were acquired at an average cost of $3.20 per share, with a total value of $1,773,600.00. Following the completion of the acquisition, the insider now directly owns 1,625,678 shares in the company, valued at $5,202,169.60. This trade represents a 51.73 % increase in their position. The disclosure for this purchase can be found here. Insiders own 14.50% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.